SH-SY5Y neuronal-like differentiation
Materials Required
Principle
SH-SY5Y neuronal-like differentiation uses defined culture conditions to shift proliferative human neuroblastoma cells toward a neuron-like state, mainly assessed by reduced proliferation, neurite extension, neuronal-marker expression, and, in some protocols, increased dependence on neurotrophic support[1][2][3][4][5]. Retinoic acid (RA) is commonly used for the first differentiation phase, and sequential RA followed by brain-derived neurotrophic factor (BDNF) in serum-free medium is a well-characterized approach for generating neuron-like SH-SY5Y cultures with extensive neurite outgrowth[1][2][6]. The primary readouts are morphology-based neurite outgrowth and marker-based confirmation using proteins such as βIII-tubulin, MAP2, GAP43, synaptophysin, NeuN, NSE, TH, or related neuronal/synaptic markers, depending on the study endpoint[2][3][4][7][8].
MCE has not independently verified the accuracy of these methods. They are for reference only.
Experimental Materials
• Use SH-SY5Y cells maintained under standard mammalian cell-culture conditions; published protocols used DMEM-based growth medium with fetal bovine serum for maintenance before differentiation[2][3].
• Use all-trans retinoic acid for the RA induction phase, with commonly reported RA differentiation at 10 µM for about 3-5 days in low-serum or serum-free conditions, and use BDNF at 50 ng/mL for the neurotrophic maturation phase when following sequential RA/BDNF protocols[1][2][3][5][6].
• Use Neurobasal-A or Neurobasal-type medium with B27 supplement, glutamine or GlutaMAX, penicillin/streptomycin, and, in some protocols, KCl during the BDNF-containing stage[2][3].
• Use laminin or Matrigel-coated culture surfaces when following protocols that explicitly included extracellular matrix coating to support attachment and neurite outgrowth[2][3][4].
• Use βIII-tubulin and GAP43 detection when confirming biochemical differentiation in the IGF-1/laminin protocol, and use βIII-tubulin, MAP2, synaptophysin, NeuN, NSE, TH, or related neuronal/synaptic markers when confirming RAor RA/BDNF-associated neuronal differentiation[2][3][4][7][8].
• Use Hoechst or DAPI nuclear staining for cell counting and morphology analysis, and use viability assays such as LIVE/DEAD staining when the endpoint requires density or toxicity assessment[3].
• Use a humidified 37°C, 5% CO2 incubator for SH-SY5Y culture and differentiation, a biosafety cabinet for sterile handling, standard tissue-culture plates or imaging plates, and fluorescence or high-content microscopy for neurite and marker analysis[2][3].
• Use image-analysis software or validated neurite-analysis pipelines when quantifying neurite length, neurite branching, nuclei count, or marker intensity[3][4].
• Use all-trans retinoic acid for the RA induction phase, with commonly reported RA differentiation at 10 µM for about 3-5 days in low-serum or serum-free conditions, and use BDNF at 50 ng/mL for the neurotrophic maturation phase when following sequential RA/BDNF protocols[1][2][3][5][6].
• Use Neurobasal-A or Neurobasal-type medium with B27 supplement, glutamine or GlutaMAX, penicillin/streptomycin, and, in some protocols, KCl during the BDNF-containing stage[2][3].
• Use laminin or Matrigel-coated culture surfaces when following protocols that explicitly included extracellular matrix coating to support attachment and neurite outgrowth[2][3][4].
• Use βIII-tubulin and GAP43 detection when confirming biochemical differentiation in the IGF-1/laminin protocol, and use βIII-tubulin, MAP2, synaptophysin, NeuN, NSE, TH, or related neuronal/synaptic markers when confirming RAor RA/BDNF-associated neuronal differentiation[2][3][4][7][8].
• Use Hoechst or DAPI nuclear staining for cell counting and morphology analysis, and use viability assays such as LIVE/DEAD staining when the endpoint requires density or toxicity assessment[3].
• Use a humidified 37°C, 5% CO2 incubator for SH-SY5Y culture and differentiation, a biosafety cabinet for sterile handling, standard tissue-culture plates or imaging plates, and fluorescence or high-content microscopy for neurite and marker analysis[2][3].
• Use image-analysis software or validated neurite-analysis pipelines when quantifying neurite length, neurite branching, nuclei count, or marker intensity[3][4].
Experimental Procedure
• Before differentiation, expand SH-SY5Y cells in growth medium and seed them onto an extracellular-matrix-coated surface if the selected protocol requires coating; Matrigel coating at 1:100 dilution was used in a 96-well differentiation workflow, and laminin-coated surfaces were used in an IGF-1 differentiation workflow[3][4].
• For high-throughput 96-well neurite analysis, seed 2,500 cells/well because this density provided space for neurite tracing without reducing viability in the cited 96-well study[3].
• For general RA/BDNF differentiation, begin with adherent cells at a low enough density to allow neurite extension and avoid overconfluence during the differentiation period[1][2][3].
• Prepare Stage I RA medium using DMEM-based medium with low serum and 10 µM RA when following the RA/BDNF workflow; one 96-well protocol used DMEM with 2.5% heat-inactivated FBS, GlutaMAX, penicillin/streptomycin, and 10 µM RA[3].
• Prepare Stage II BDNF medium using Neurobasal-A medium with B27, GlutaMAX, penicillin/streptomycin, 50 ng/mL BDNF, and 20 mM KCl when following the Dravid high-throughput workflow[3].
• Prepare RA-containing medium immediately according to laboratory chemical-safety practice, but do not add unsupported storage or handling rules beyond what the cited protocols report[1][2][3].
• A literature-supported RA/BDNF workflow is: seed SH-SY5Y cells on a coated culture surface, allow attachment, replace growth medium with RA-containing Stage I medium, culture for 5 days, then replace with BDNF-containing Stage II medium and culture for another 5 days[1][3][6].
• In the high-throughput 96-well workflow, a 1-hour room-temperature pre-incubation after plating improved plating homogeneity before transfer to the 37°C incubator[3].
• This 10-day RA/BDNF sequence produces extensive neurite outgrowth and is suitable for neurite-outgrowth assays and neuronal-marker analysis[1][3][6].
• An alternative literature-supported workflow for biochemical differentiation in adhesion/migration studies is to culture SH-SY5Y cells on laminin in serum-free DMEM with 50 nM IGF-1 for 72 hours; this condition increased neurite outgrowth and βIII-tubulin/GAP43 protein levels compared with undifferentiated controls in that study[4].
• RA alone can induce morphology and transcriptional changes toward a neuronal or dopaminergic-like phenotype, but at least one optimization study found that RA-induced morphological differentiation did not match IGF-1 for biochemical differentiation under its tested conditions[4][7][8].
• For fixation and immunostaining in the 96-well RA/BDNF workflow, the cited study removed half of the medium, added an equal volume of 4% paraformaldehyde to reach 2% paraformaldehyde for 2 minutes, then replaced it with 4% paraformaldehyde for 10 minutes before staining[3].
• For endpoint imaging, acquire nuclei and neuronal-marker channels and quantify neurite extension, branching, cell number, and marker intensity using the same imaging settings across experimental groups within an experiment[3][4].
• Interpret differentiation by comparing differentiated cells with undifferentiated controls for neurite morphology, cell density, viability, and neuronal-marker expression[3][4][7].
• Use untreated or growth-medium-maintained SH-SY5Y cultures as negative/undifferentiated controls, and use the selected validated differentiation condition, such as RA/BDNF for 10 days or IGF-1 on laminin for 72 hours, as the positive differentiation condition[3][4].
• Report biological replicates and technical replicate wells when used; the 96-well optimization study used replicate wells for plating-homogeneity and density experiments, and the IGF-1 optimization study reported n = 3 for morphology and marker quantification[3][4].
• For high-throughput 96-well neurite analysis, seed 2,500 cells/well because this density provided space for neurite tracing without reducing viability in the cited 96-well study[3].
• For general RA/BDNF differentiation, begin with adherent cells at a low enough density to allow neurite extension and avoid overconfluence during the differentiation period[1][2][3].
• Prepare Stage I RA medium using DMEM-based medium with low serum and 10 µM RA when following the RA/BDNF workflow; one 96-well protocol used DMEM with 2.5% heat-inactivated FBS, GlutaMAX, penicillin/streptomycin, and 10 µM RA[3].
• Prepare Stage II BDNF medium using Neurobasal-A medium with B27, GlutaMAX, penicillin/streptomycin, 50 ng/mL BDNF, and 20 mM KCl when following the Dravid high-throughput workflow[3].
• Prepare RA-containing medium immediately according to laboratory chemical-safety practice, but do not add unsupported storage or handling rules beyond what the cited protocols report[1][2][3].
• A literature-supported RA/BDNF workflow is: seed SH-SY5Y cells on a coated culture surface, allow attachment, replace growth medium with RA-containing Stage I medium, culture for 5 days, then replace with BDNF-containing Stage II medium and culture for another 5 days[1][3][6].
• In the high-throughput 96-well workflow, a 1-hour room-temperature pre-incubation after plating improved plating homogeneity before transfer to the 37°C incubator[3].
• This 10-day RA/BDNF sequence produces extensive neurite outgrowth and is suitable for neurite-outgrowth assays and neuronal-marker analysis[1][3][6].
• An alternative literature-supported workflow for biochemical differentiation in adhesion/migration studies is to culture SH-SY5Y cells on laminin in serum-free DMEM with 50 nM IGF-1 for 72 hours; this condition increased neurite outgrowth and βIII-tubulin/GAP43 protein levels compared with undifferentiated controls in that study[4].
• RA alone can induce morphology and transcriptional changes toward a neuronal or dopaminergic-like phenotype, but at least one optimization study found that RA-induced morphological differentiation did not match IGF-1 for biochemical differentiation under its tested conditions[4][7][8].
• For fixation and immunostaining in the 96-well RA/BDNF workflow, the cited study removed half of the medium, added an equal volume of 4% paraformaldehyde to reach 2% paraformaldehyde for 2 minutes, then replaced it with 4% paraformaldehyde for 10 minutes before staining[3].
• For endpoint imaging, acquire nuclei and neuronal-marker channels and quantify neurite extension, branching, cell number, and marker intensity using the same imaging settings across experimental groups within an experiment[3][4].
• Interpret differentiation by comparing differentiated cells with undifferentiated controls for neurite morphology, cell density, viability, and neuronal-marker expression[3][4][7].
• Use untreated or growth-medium-maintained SH-SY5Y cultures as negative/undifferentiated controls, and use the selected validated differentiation condition, such as RA/BDNF for 10 days or IGF-1 on laminin for 72 hours, as the positive differentiation condition[3][4].
• Report biological replicates and technical replicate wells when used; the 96-well optimization study used replicate wells for plating-homogeneity and density experiments, and the IGF-1 optimization study reported n = 3 for morphology and marker quantification[3][4].
Troubleshooting
Uneven cell distribution in 96-well plates.
Possible Cause:Cells can concentrate in uneven regions of the well, which affects imaging and neurite analysis
Literature-supported Solution:
After plating, pre-incubate plates at room temperature for 1 hour before transfer to the incubator; this improved plating homogeneity in the 96-well SH-SY5Y differentiation study[3].
Neurites are difficult to trace in 96-well neurite-outgrowth assays.
Possible Cause:Initial seeding density can become too high after proliferation during the differentiation period
Literature-supported Solution:
For the cited 96-well RA/BDNF workflow, seed 2,500 cells/well, which balanced neurite visualization and viability better than higher densities[3].
Differentiated cells form floating clusters after detachment and replating.
Possible Cause:Detachment reagent choice affects dissociation of terminally differentiated SH-SY5Y cells
Literature-supported Solution:
In the cited comparison, trypsin-EDTA 0.05%, Versene, and gentle cell dissociation reagent supported replating as dissociated cultures, whereas Accutase and Dispase led to floating clusters[3].
RA-treated cells show neurite-like morphology but weak biochemical differentiation for a specific adhesion/migration endpoint.
Possible Cause:RA can produce morphological differentiation without the strongest increase in the tested biochemical markers under some conditions
Literature-supported Solution:
For adhesion/migration studies, the cited optimization study selected laminin plus serum-free DMEM with 50 nM IGF-1 for 72 hours because it increased βIII-tubulin and GAP43 more than RA under the tested conditions[4].
References:
- [1]. Encinas M, et al. Sequential treatment of SH-SY5Y cells with retinoic acid and brain-derived neurotrophic factor gives rise to fully differentiated, neurotrophic factor-dependent, human neuron-like cells. J Neurochem. 2000;75(3):991-1003. [Content Brief]
- [2]. Shipley MM, et al. Differentiation of the SH-SY5Y human neuroblastoma cell line. J Vis Exp. 2016;(108):53193. [Content Brief]
- [3]. Dravid A, et al. Optimised techniques for high-throughput screening of differentiated SH-SY5Y cells and application for neurite outgrowth assays. Sci Rep. 2021;11(1):23935. [Content Brief]
- [4]. Dwane S, et al. Optimising parameters for the differentiation of SH-SY5Y cells to study cell adhesion and cell migration. BMC Res Notes. 2013;6:366. [Content Brief]
- [5]. Kovalevich J, et al. Considerations for the use of SH-SY5Y neuroblastoma cells in neurobiology. Methods Mol Biol. 2013;1078:9-21. [Content Brief]
- [6]. Targett IL, et al. Differentiation of SH-SY5Y neuroblastoma cells using retinoic acid and BDNF: a model for neuronal and synaptic differentiation in neurodegeneration. In Vitro Cell Dev Biol Anim. 2024;60(9):1058-1067. [Content Brief]
- [7]. Cheung YT, et al. Effects of all-trans-retinoic acid on human SH-SY5Y neuroblastoma as in vitro model in neurotoxicity research. Neurotoxicology. 2009;30(1):127-135. [Content Brief]
- [8]. Korecka JA, et al. Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013;8(5):e63862. [Content Brief]
LinkedIn
Researchgate
Instagram
X
Facebook
WhatsApp
Reddit
Mail